EA029096B1 - Твердая лекарственная форма для перорального введения, содержащая метилналтрексон - Google Patents

Твердая лекарственная форма для перорального введения, содержащая метилналтрексон Download PDF

Info

Publication number
EA029096B1
EA029096B1 EA201270741A EA201270741A EA029096B1 EA 029096 B1 EA029096 B1 EA 029096B1 EA 201270741 A EA201270741 A EA 201270741A EA 201270741 A EA201270741 A EA 201270741A EA 029096 B1 EA029096 B1 EA 029096B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methylnaltrexone
pharmaceutically acceptable
acceptable excipient
certain embodiments
composition
Prior art date
Application number
EA201270741A
Other languages
English (en)
Russian (ru)
Other versions
EA201270741A1 (ru
Inventor
Сиед М. Шах
Кристофер Ричард Диорио
Эрик К. Эрншпергер
Сюй Мэн
Шареффи Кадум А. Ал
Джонатан Марк Коэн
Original Assignee
Вайет Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA029096(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайет Ллк filed Critical Вайет Ллк
Publication of EA201270741A1 publication Critical patent/EA201270741A1/ru
Publication of EA029096B1 publication Critical patent/EA029096B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201270741A 2010-03-11 2011-03-10 Твердая лекарственная форма для перорального введения, содержащая метилналтрексон EA029096B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
PCT/US2011/027913 WO2011112816A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Publications (2)

Publication Number Publication Date
EA201270741A1 EA201270741A1 (ru) 2013-02-28
EA029096B1 true EA029096B1 (ru) 2018-02-28

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270741A EA029096B1 (ru) 2010-03-11 2011-03-10 Твердая лекарственная форма для перорального введения, содержащая метилналтрексон

Country Status (32)

Country Link
US (8) US8524276B2 (enExample)
EP (2) EP2371357B1 (enExample)
JP (4) JP6143409B2 (enExample)
KR (2) KR101913102B1 (enExample)
CN (2) CN107308125B (enExample)
AR (1) AR080491A1 (enExample)
AU (1) AU2011224275B2 (enExample)
BR (1) BR112012022873B1 (enExample)
CA (1) CA2789798C (enExample)
CL (1) CL2012002192A1 (enExample)
CO (1) CO6630134A2 (enExample)
CR (1) CR20120476A (enExample)
EA (1) EA029096B1 (enExample)
EC (1) ECSP12012208A (enExample)
ES (1) ES2623926T3 (enExample)
GE (1) GEP201606550B (enExample)
GT (1) GT201200247A (enExample)
HU (1) HUE033133T2 (enExample)
IL (1) IL221452A (enExample)
MA (1) MA34146B1 (enExample)
MX (2) MX349145B (enExample)
MY (1) MY160727A (enExample)
NZ (3) NZ601595A (enExample)
PE (1) PE20130063A1 (enExample)
PH (1) PH12012501622A1 (enExample)
PL (2) PL2371357T3 (enExample)
SG (3) SG10201501821RA (enExample)
TN (1) TN2012000392A1 (enExample)
TW (2) TWI605814B (enExample)
UA (2) UA123856C2 (enExample)
WO (1) WO2011112816A1 (enExample)
ZA (2) ZA201206662B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
TWI605814B (zh) 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
WO2013096444A1 (en) * 2011-12-19 2013-06-27 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3177146A4 (en) * 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3206491B1 (en) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
WO2020225395A1 (en) * 2019-05-07 2020-11-12 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144510A1 (en) * 2001-11-29 2003-07-31 Schering Corporation Preparation of pharmaceutical salts
WO2008121860A1 (en) * 2007-03-29 2008-10-09 Wyeth Peripheral opioid receptor and antagonists and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
EP1387673B1 (en) * 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
WO2002098422A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
AU2003220290B2 (en) 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
AU2004259208B2 (en) * 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
CA2550071A1 (en) 2003-12-19 2005-07-07 Schering Corporation Pharmaceutical compositions
US20070148232A1 (en) * 2003-12-31 2007-06-28 Pfizer Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
EP1809579B1 (en) 2004-09-30 2012-08-08 Becton, Dickinson and Company Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
ATE553787T1 (de) * 2006-08-16 2012-05-15 Novartis Ag Vorübergehende lichtbleichung von farbigen linsenpflegelösungen
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
CN102014907A (zh) * 2008-05-07 2011-04-13 尼克塔治疗公司 外周作用阿片拮抗剂的口服给药
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
TWI605814B (zh) 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144510A1 (en) * 2001-11-29 2003-07-31 Schering Corporation Preparation of pharmaceutical salts
WO2008121860A1 (en) * 2007-03-29 2008-10-09 Wyeth Peripheral opioid receptor and antagonists and uses thereof

Also Published As

Publication number Publication date
JP2016029054A (ja) 2016-03-03
MA34146B1 (fr) 2013-04-03
EP2371357B1 (en) 2017-02-01
US20120070495A1 (en) 2012-03-22
US20140249171A1 (en) 2014-09-04
EP3178472A1 (en) 2017-06-14
MY160727A (en) 2017-03-15
JP2019034958A (ja) 2019-03-07
HUE033133T2 (en) 2017-11-28
TN2012000392A1 (en) 2014-01-30
JP6429955B2 (ja) 2018-11-28
MX349145B (es) 2017-07-14
UA123856C2 (uk) 2021-06-16
US20160206612A1 (en) 2016-07-21
PH12012501622A1 (en) 2012-11-05
IL221452A (en) 2017-07-31
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
US10307417B2 (en) 2019-06-04
CL2012002192A1 (es) 2012-09-28
ECSP12012208A (es) 2015-03-31
JP2017206553A (ja) 2017-11-24
EA201270741A1 (ru) 2013-02-28
SG10201501821RA (en) 2015-05-28
JP2011190259A (ja) 2011-09-29
NZ703564A (en) 2016-08-26
TW201141479A (en) 2011-12-01
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
CR20120476A (es) 2012-11-30
NZ702826A (en) 2016-08-26
IL221452A0 (en) 2012-10-31
TWI605814B (zh) 2017-11-21
ES2623926T3 (es) 2017-07-12
CO6630134A2 (es) 2013-03-01
EP3178472B1 (en) 2021-10-27
US9314461B2 (en) 2016-04-19
CN102918039B (zh) 2017-06-09
CN107308125B (zh) 2021-07-16
AR080491A1 (es) 2012-04-11
JP6143409B2 (ja) 2017-06-07
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
US20200121673A1 (en) 2020-04-23
US20190314365A1 (en) 2019-10-17
UA111717C2 (uk) 2016-06-10
KR20130010900A (ko) 2013-01-29
MX2012009125A (es) 2012-09-07
WO2011112816A1 (en) 2011-09-15
AU2011224275A1 (en) 2012-08-23
EP2371357A1 (en) 2011-10-05
CN102918039A (zh) 2013-02-06
SG10201606618PA (en) 2016-09-29
US10376505B2 (en) 2019-08-13
US20190117645A1 (en) 2019-04-25
NZ601595A (en) 2015-01-30
US8524276B2 (en) 2013-09-03
KR101913102B1 (ko) 2018-10-31
JP6647368B2 (ja) 2020-02-14
CA2789798C (en) 2020-09-22
GT201200247A (es) 2013-09-11
US10507206B2 (en) 2019-12-17
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
US20130330407A1 (en) 2013-12-12
PE20130063A1 (es) 2013-02-11
TW201622724A (zh) 2016-07-01
HK1245673A1 (zh) 2018-08-31
BR112012022873A2 (pt) 2016-08-30
MX368805B (es) 2019-10-17
ZA201206662B (en) 2026-05-27
GEP201606550B (en) 2016-10-10
PL2371357T3 (pl) 2017-09-29
US20190117646A1 (en) 2019-04-25
BR112012022873B1 (pt) 2021-09-14
CN107308125A (zh) 2017-11-03
SG183133A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
JP6647368B2 (ja) メチルナルトレキソンの経口製剤および親油性塩
AU2013203559B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
AU2016200133B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
HK1245673B (en) Oral formulations and lipophilic salts of methylnaltrexone
HK1158534B (en) Oral formulations and lipophilic salts of methylnaltrexone
HK1158534A (en) Oral formulations and lipophilic salts of methylnaltrexone